Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23840| Title: | Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. | Austin Authors: | Srinivasan, Ashish ;De Cruz, Peter P ;van Langenberg, Daniel R | Affiliation: | Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia Gastroenterology and Hepatology Medicine (University of Melbourne) Department of Medicine, Monash University, Melbourne, Victoria, Australia |
Issue Date: | Aug-2020 | Publication information: | Alimentary Pharmacology & Therapeutics 2020; 52(3): 561-562 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23840 | DOI: | 10.1111/apt.15862 | ORCID: | 0000-0001-5952-1570 0000-0003-3662-6307 |
Journal: | Alimentary Pharmacology & Therapeutics | PubMed URL: | 32656826 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.